Heather D. Turner Sells 12,214 Shares of Atara Biotherapeutics Inc (ATRA) Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) EVP Heather D. Turner sold 12,214 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $38.01, for a total transaction of $464,254.14. Following the transaction, the executive vice president now directly owns 77,112 shares in the company, valued at $2,931,027.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) traded down $2.23 during mid-day trading on Monday, reaching $39.48. 1,388,248 shares of the company’s stock were exchanged, compared to its average volume of 1,370,000. The firm has a market capitalization of $1,210.00, a PE ratio of -11.38 and a beta of 2.71. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $44.00.

ATRA has been the topic of a number of recent research reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. BidaskClub raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research report on Wednesday, January 3rd. Finally, Cowen initiated coverage on shares of Atara Biotherapeutics in a research report on Friday, January 26th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.60.

A number of hedge funds have recently made changes to their positions in the business. Carillon Tower Advisers Inc. acquired a new position in Atara Biotherapeutics during the fourth quarter valued at approximately $23,284,000. Neuberger Berman Group LLC lifted its position in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after buying an additional 147,061 shares in the last quarter. Artal Group S.A. raised its stake in shares of Atara Biotherapeutics by 66.7% during the fourth quarter. Artal Group S.A. now owns 1,000,000 shares of the biotechnology company’s stock valued at $18,100,000 after purchasing an additional 400,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Atara Biotherapeutics by 1.7% during the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after purchasing an additional 13,952 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Atara Biotherapeutics by 12.0% during the second quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock valued at $4,183,000 after purchasing an additional 32,065 shares during the period. 69.58% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Heather D. Turner Sells 12,214 Shares of Atara Biotherapeutics Inc (ATRA) Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/heather-d-turner-sells-12214-shares-of-atara-biotherapeutics-inc-atra-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply